Huadong Medicine Co., Ltd Sustainability Profile
Huadong Medicine Co., Ltd., a prominent player in the pharmaceutical industry, is headquartered in China (CN) and operates extensively across various regions. Founded in 1993, the company has established itself as a leader in the development, manufacturing, and distribution of high-quality pharmaceutical products. Specialising in innovative medicines, Huadong Medicine focuses on areas such as oncology, cardiovascular health, and central nervous system disorders. Their commitment to research and development has led to the creation of unique formulations that address unmet medical needs, setting them apart in a competitive market. With a strong market position, Huadong Medicine has achieved significant milestones, including numerous product approvals and partnerships that enhance its global reach. The company’s dedication to quality and innovation continues to drive its success in the ever-evolving healthcare landscape.
DitchCarbon Score
How does Huadong Medicine Co., Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Huadong Medicine Co., Ltd's score of 26 is lower than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Huadong Medicine Co., Ltd's reported carbon emissions
In 2023, Huadong Medicine Co., Ltd reported total Scope 1 emissions of approximately 14,288,850 kg CO2e. The company's combined Scope 1 and 2 emissions reached about 152,103,450 kg CO2e. This marks an increase from 2022, when Scope 1 emissions were about 11,305,600 kg CO2e, and total Scope 1 and 2 emissions were approximately 108,596,090 kg CO2e. Despite these figures, Huadong Medicine has not disclosed any specific reduction targets or initiatives aimed at decreasing its carbon footprint. The company does not currently report on Scope 2 or Scope 3 emissions, which limits the comprehensiveness of its climate impact assessment. Furthermore, there are no climate pledges or commitments to industry-standard initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP) noted in their disclosures. Overall, while Huadong Medicine Co., Ltd has made strides in reporting its emissions, the absence of reduction targets and broader emissions data suggests a need for enhanced climate commitments and transparency in its sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 11,305,600 | 00,000,000 |
| Scope 2 | - | - |
| Scope 3 | - | - |
How Carbon Intensive is Huadong Medicine Co., Ltd's Industry?
How Carbon Intensive is Huadong Medicine Co., Ltd's Location?
Huadong Medicine Co., Ltd's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Huadong Medicine Co., Ltd has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
